AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38166991 — intervention group
Group type: COMPARATOR
Intervention: Spectrophotometric measurement
Number of subjects: 61
Study 38167019 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab with methotrexate co-treatment
Number of subjects: 28
Study 38167019 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab monotherapy
Number of subjects: 28
Study 38167022 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model consisting of nine radiomic features
Number of subjects: 140
Study 38167022 — intervention group
Group type: COMPARATOR
Intervention: Traditional model consisting of serum β-D-glucan levels
Number of subjects: 140
Study 38167022 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiomics features and serum β-D-glucan levels
Number of subjects: 140
Study 38167046 — intervention group
Group type: EXPERIMENTAL
Intervention: BASIS-T implementation strategy
Number of subjects: 276
Study 38167046 — intervention group
Group type: COMPARATOR
Intervention: Active Comparison Control (ACC)
Number of subjects: 276
Study 38167064 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% losartan potassium loaded in ethosomal gel
Number of subjects: 46
Study 38167064 — intervention group
Group type: COMPARATOR
Intervention: 10% triamcinolone acetonide (intralesional injections)
Number of subjects: 46
Study 38167068 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR with sac embolization (SE) using metal coils
Number of subjects: 100
Study 38167068 — intervention group
Group type: COMPARATOR
Intervention: Standard EVAR
Number of subjects: 100
Study 38167068 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR with sac embolization (SE)
Number of subjects: 100
Study 38167115 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) administered via continuous intravenous administration for 7 days
Number of subjects: 600
Study 38167115 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) administered via continuous intravenous administration for 7 days
Number of subjects: 600
Study 38167115 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 600
Study 38167175 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 80
Study 38167175 — intervention group
Group type: COMPARATOR
Intervention: Sham RIC
Number of subjects: 80
Study 38167178 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (60 min duration, 2 mA for 10 sessions)
Number of subjects: 76
Study 38167178 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (60 min duration, placebo treatment for 10 sessions)
Number of subjects: 76
Study 38167178 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 76
Study 38167178 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 76
Study 38167204 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion intervention group receiving four weekly 1-h sessions with induction and hypnosis
Number of subjects: 90
Study 38167204 — intervention group
Group type: COMPARATOR
Intervention: Active control group receiving four weekly 1-h sessions of induction and mindfulness
Number of subjects: 90
Study 38167204 — intervention group
Group type: COMPARATOR
Intervention: Passive control group without intervention
Number of subjects: 90
Study 38167204 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 38167206 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes with basic care counselling
Number of subjects: 600
Study 38167206 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine pouches with basic care counselling
Number of subjects: 600
Study 38167206 — intervention group
Group type: COMPARATOR
Intervention: Basic care counselling only
Number of subjects: 600
Study 38167216 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenteric fixation method (MEFIX)
Number of subjects: 0
Study 38167216 — intervention group
Group type: COMPARATOR
Intervention: Conventional Petersen's defect closure method (CLOSURE)
Number of subjects: 0
Study 38167251 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Clock and Recall (DCR)
Number of subjects: 706
Study 38167251 — intervention group
Group type: COMPARATOR
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 706
Study 38167261 — intervention group
Group type: EXPERIMENTAL
Intervention: Siyakhana intervention (3 days of training in depression and substance use focused on psychoeducation, evidence-based skills, and self-care strategies)
Number of subjects: 6
Study 38167261 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy (social contact with people with lived experience of depression/SU during training and clinical supervision)
Number of subjects: 6
Study 38167285 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact force of the tracheal tube on the tongue during general anaesthesia in different surgical positions
Number of subjects: 54
Study 38167315 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch-massage® sessions (15 minutes, once a week for three weeks)
Number of subjects: 62
Study 38167315 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving equivalent amount of quiet time (15 minutes, once a week for three weeks)
Number of subjects: 62
Study 38167321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncuria BC multiplex immunoassay
Number of subjects: 36
Study 38167321 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 38167339 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week hypofractionated radiotherapy (26 Gy in 5 fractions)
Number of subjects: 1018
Study 38167339 — intervention group
Group type: COMPARATOR
Intervention: 2 weeks conventional radiotherapy (34 Gy in 10 fractions)
Number of subjects: 1018
Study 38167339 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week hypofractionated radiotherapy
Number of subjects: 1018
Study 38167339 — intervention group
Group type: COMPARATOR
Intervention: 2 weeks conventional radiotherapy
Number of subjects: 1018
Study 38167483 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38167503 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (ipilimumab plus nivolumab) followed by BRAF/MEK inhibition (encorafenib plus binimetinib)
Number of subjects: 0
Study 38167503 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week induction course of targeted therapy (encorafenib plus binimetinib) followed by immunotherapy
Number of subjects: 0
Study 38167503 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (ipilimumab plus nivolumab)
Number of subjects: 0
Study 38167540 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min supine time group
Number of subjects: 120
Study 38167540 — intervention group
Group type: COMPARATOR
Intervention: 2-h supine time group
Number of subjects: 120
Study 38167585 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week exercise program
Number of subjects: 24
Study 38167585 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 38167647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (OFA) as part of reduced intensity conditioning (RIC) regimen
Number of subjects: 33
Study 38167806 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant camrelizumab and apatinib combined with nab-paclitaxel plus S-1 (CA-SAP)
Number of subjects: 104
Study 38167806 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy SAP alone (SAP)
Number of subjects: 104
Study 38167882 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar androgen therapy (BAT) with nivolumab
Number of subjects: 45
Study 38167882 — intervention group
Group type: COMPARATOR
Intervention: Bipolar androgen therapy (BAT)
Number of subjects: 45
Study 38167928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) lowering (target 110 to <130 mmHg)
Number of subjects: 8206
Study 38167937 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab plus SOX/XELOX
Number of subjects: 108
Study 38167937 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (SOX/XELOX)
Number of subjects: 108
Study 38167960 — intervention group
Group type: EXPERIMENTAL
Intervention: Subscapularis fatty infiltration subgroup of NBPP patients
Number of subjects: 16
Study 38167960 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder rotator muscle strength assessment using isokinetic dynamometer
Number of subjects: 16
Study 38167960 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment of subscapularis and infraspinatus muscles
Number of subjects: 16
Study 38167960 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mallet score
Number of subjects: 16
Study 38168134 — intervention group
Group type: EXPERIMENTAL
Intervention: GP40141
Number of subjects: 56
Study 38168442 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% 5-Fluorouracil (5-FU) cream, 2g self-administered intravaginally every other week for eight applications.
Number of subjects: 12
Study 38168442 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% 5-Fluorouracil (5-FU) cream
Number of subjects: 12
Study 38168815 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM group with multistranded Stainless Steel wires
Number of subjects: 75
Study 38168815 — intervention group
Group type: COMPARATOR
Intervention: Chairside group with Stainless Steel Ortho-FlexTech wires
Number of subjects: 75
Study 38168815 — intervention group
Group type: COMPARATOR
Intervention: Lab group with multistranded wires
Number of subjects: 75
Study 38168815 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 75
Study 38169391 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) + mindfulness meditation (MBM) with implementation intention (II)
Number of subjects: 170
Study 38169391 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing (MI)
Number of subjects: 170
Study 38169423 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training followed by Aerobic Training (SAG, n=16)
Number of subjects: 33
Study 38169423 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Training followed by Strength Training (ASG, n=17)
Number of subjects: 33
Study 38169423 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise sequences (SAG and ASG)
Number of subjects: 33
Study 38169488 — intervention group
Group type: EXPERIMENTAL
Intervention: LPG cookstoves and fuel
Number of subjects: 3200
Study 38169488 — intervention group
Group type: COMPARATOR
Intervention: Biomass cookstoves
Number of subjects: 3200
Study 38169489 — intervention group
Group type: EXPERIMENTAL
Intervention: LPG cookstove with continuous free fuel delivery for 18 months
Number of subjects: 3200
Study 38169489 — intervention group
Group type: COMPARATOR
Intervention: Biomass cookstove
Number of subjects: 3200
Study 38169489 — intervention group
Group type: EXPERIMENTAL
Intervention: LPG cookstove
Number of subjects: 3200
Study 38169574 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose QiShen YiQi Dripping Pills (QSYQ)
Number of subjects: 228
Study 38169574 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose QiShen YiQi Dripping Pills (QSYQ)
Number of subjects: 228
Study 38169574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 38169630 — intervention group
Group type: EXPERIMENTAL
Intervention: Children during the pandemic community lockdown
Number of subjects: 94
Study 38169630 — intervention group
Group type: COMPARATOR
Intervention: Children before the pandemic community lockdown
Number of subjects: 94
Study 38169630 — intervention group
Group type: COMPARATOR
Intervention: Children following the pandemic community lockdown
Number of subjects: 94
Study 38169667 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from the pharmacy regarding self-care of the feet
Number of subjects: 17
Study 38169667 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management practices
Number of subjects: 17
Study 38169667 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of risk using MyFoot Diabetes software
Number of subjects: 17
Study 38169667 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professional risk assessment
Number of subjects: 17
Study 38169667 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestions for pharmacy support
Number of subjects: 17
Study 38169749 — intervention group
Group type: EXPERIMENTAL
Intervention: Elacestrant (ELA)
Number of subjects: 0
Study 38169749 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 0
Study 38169790 — intervention group
Group type: EXPERIMENTAL
Intervention: SW-BIC-213 (25 μg)
Number of subjects: 2403
Study 38169790 — intervention group
Group type: COMPARATOR
Intervention: BBIBP (homologous booster)
Number of subjects: 2403
Study 38169790 — intervention group
Group type: EXPERIMENTAL
Intervention: SW-BIC-213
Number of subjects: 2403
Study 38169790 — intervention group
Group type: COMPARATOR
Intervention: BBIBP
Number of subjects: 2403
Study 38169790 — intervention group
Group type: EXPERIMENTAL
Intervention: SW-BIC-213 and BBIBP
Number of subjects: 2403
Study 38169864 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of PD
Number of subjects: 395
Study 38169864 — intervention group
Group type: COMPARATOR
Intervention: No family history of PD
Number of subjects: 395
Study 38169917 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 28
Study 38169944 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccination
Number of subjects: 34489
Study 38169944 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-vaccinated)
Number of subjects: 34489
Study 38169960 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular vesicles (EVs) derived from adipose tissue
Number of subjects: 0
Study 38169960 — intervention group
Group type: EXPERIMENTAL
Intervention: Current EVs-based therapeutic strategies
Number of subjects: 0
Study 38170033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily with ASA 80 mg once daily
Number of subjects: 437
Study 38170033 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg once daily with ASA 80 mg once daily
Number of subjects: 437
Study 38170085 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rehabilitation alone
Number of subjects: 61
Study 38170085 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial patellofemoral ligament reconstruction and active rehabilitation
Number of subjects: 61
Study 38170085 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline single leg hop for distance
Number of subjects: 61
Study 38170085 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline triple hop for distance
Number of subjects: 61
Study 38170085 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee injury and Osteoarthritis Outcome Score (KOOS)
Number of subjects: 61
Study 38170085 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb Symmetry Index (LSI)
Number of subjects: 61
Study 38170185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine treatment (dosage and duration not available)
Number of subjects: 0
Study 38170227 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 1000
Study 38170227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 38170246 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffolds (ABSORB BRS, Abbott Vascular)
Number of subjects: 35
Study 38170248 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF patients
Number of subjects: 68
Study 38170248 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalized patients during follow-up
Number of subjects: 68
Study 38170248 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired left atrial (LA) function at rest
Number of subjects: 68
Study 38170248 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired left atrial (LA) function during stress
Number of subjects: 68
Study 38170248 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-derived atrial function parameters at rest and during exercise-stress
Number of subjects: 68
Study 38170248 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-Feature Tracking LA Es/Ee
Number of subjects: 68
Study 38170248 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-CMR derived LA long axis strain
Number of subjects: 68
Study 38170248 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial function
Number of subjects: 68
Study 38170249 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 levels at ICU admission
Number of subjects: 172
Study 38170249 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 levels above vs. below the median
Number of subjects: 172
Study 38170256 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium valproate (SV) applied twice daily
Number of subjects: 66
Study 38170256 — intervention group
Group type: COMPARATOR
Intervention: Topical mometasone furoate lotion applied twice daily
Number of subjects: 66
Study 38170256 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium valproate (SV) and topical steroids
Number of subjects: 66
Study 38170263 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional employment after VAD implantation
Number of subjects: 375
Study 38170263 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 375
Study 38170263 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 375
Study 38170263 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) for employed patients
Number of subjects: 375
Study 38170263 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment and history of adverse events
Number of subjects: 375
Study 38170263 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HRQoL perception
Number of subjects: 375
Study 38170301 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 122
Study 38170301 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 122
Study 38170301 — intervention group
Group type: COMPARATOR
Intervention: Nausea (having vs. not having)
Number of subjects: 122
Study 38170301 — intervention group
Group type: COMPARATOR
Intervention: Pain (having vs. not having)
Number of subjects: 122
Study 38170301 — intervention group
Group type: COMPARATOR
Intervention: Patients' rating of the exercise intervention
Number of subjects: 122
Study 38170393 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI Easyhaler (PIFEH)
Number of subjects: 246
Study 38170502 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin in CARMELINA trial
Number of subjects: 13012
Study 38170502 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin in CAROLINA trial
Number of subjects: 13012
Study 38170541 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-use tDCS plus digital psychological intervention (double active)
Number of subjects: 210
Study 38170541 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-use tDCS plus digital placebo (tDCS only)
Number of subjects: 210
Study 38170541 — intervention group
Group type: COMPARATOR
Intervention: Sham home-use tDCS plus digital placebo (double sham)
Number of subjects: 210
Study 38170601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.5 or 0.8 mEq/kg lean body weight per day) for 28 weeks
Number of subjects: 194
Study 38170601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 38170674 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38170741 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (INO) at a maximum tolerated dose (MTD) of 0.6 mg/m2, administered on day 1 of 28-day cycles.
Number of subjects: 18
Study 38170953 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplant (aHSCT)
Number of subjects: 1
Study 38171034 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day of Ca-HMB with resistance training (3 sessions/week)
Number of subjects: 0
Study 38171034 — intervention group
Group type: COMPARATOR
Intervention: Placebo with resistance training (3 sessions/week)
Number of subjects: 0
Study 38171156 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib
Number of subjects: 51
Study 38171212 — intervention group
Group type: EXPERIMENTAL
Intervention: Text Message Intervention (TMI)
Number of subjects: 60
Study 38171212 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (eUC)
Number of subjects: 60
Study 38171619 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMI patients (elderly and very socially disadvantaged)
Number of subjects: 9218
Study 38171619 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke patients
Number of subjects: 9218
Study 38171620 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (gastric bypass, gastric band, or sleeve gastrectomy)
Number of subjects: 758
Study 38171623 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-scale take-home naloxone distribution (2019-2021)
Number of subjects: 0
Study 38171623 — intervention group
Group type: COMPARATOR
Intervention: Historic control period (2013-2017)
Number of subjects: 0
Study 38171625 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily
Number of subjects: 50
Study 38171625 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 50
Study 38171630 — intervention group
Group type: EXPERIMENTAL
Intervention: GOAL intervention (16-week program including after-school activities, parent meetings, and social networking)
Number of subjects: 882
Study 38171630 — intervention group
Group type: EXPERIMENTAL
Intervention: GOAL intervention
Number of subjects: 882
Study 38171633 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapy in addition to Treatment as Usual (TAU)
Number of subjects: 76
Study 38171633 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 76
Study 38171926 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver-directed gene therapy
Number of subjects: 0
Study 38171926 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy vectors and strategies for liver-targeting
Number of subjects: 0
Study 38171926 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy administration in a fibrotic liver
Number of subjects: 0
Study 38172296 — intervention group
Group type: EXPERIMENTAL
Intervention: ilofotase alfa
Number of subjects: 650
Study 38172296 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 650